Login to Your Account


Medivation, Astellas PREVAIL in phase III with Xtandi in PC

By Randy Osborne
Staff Writer

Wednesday, January 29, 2014
Metastatic, castration-resistant prostate cancer as a therapeutic space is heating up still more with the disclosure by Medivation Inc. and partner Astellas Pharma Inc. of powerful data with Xtandi (enzalutamide) from the Phase III study known as PREVAIL.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription